The core insight behind SynCraft is what the authors call the synthesis cliff. In medicinal chemistry, small structural changes can produce disproportionately large swings in synthetic feasibility, much as activity cliffs describe tiny modifications that dramatically alter biological potency. A molecule that is unreachable by any known reaction sequence may sit only one or two atom-level edits away from a close analogue that a retrosynthesis planner can route with ease. The trick, then, is not to abandon the original design and start over, but to find the minimal set of structural modifications that carries the molecule over the cliff while preserving everything that made it attractive in the first place: its binding interactions, its pharmacophore, its structural novelty.

Existing approaches to this problem tend to fall into two camps, and both come with costs. Post hoc filtering simply discards generated molecules that fail a synthesizability check, which wastes much of the creative output of generative models and biases libraries toward mundane chemistry. Projection-based methods go further, forcing an infeasible molecule onto the nearest point in a predefined space of synthetically accessible compounds. The problem is that this projection can wreck the very features that mattered. A key pharmacophore can be disrupted, a crucial hydrogen-bond donor can vanish, and the structural novelty that motivated the design in the first place can be flattened into something indistinguishable from existing patent literature. SynCraft rejects both strategies in favor of something more precise.

The framework reframes synthesizability optimization as a structural editing problem and hands that problem to a large language model, but with a crucial twist. Rather than asking the model to write out complete molecular structures as SMILES strings, a task at which language models are notoriously fragile because a single misplaced character can render an entire string chemically invalid, SynCraft asks the model to predict executable sequences of atom-level edits. Each edit is a discrete, verifiable operation on the existing structure, applied through cheminformatics tooling such as RDKit. This division of labor plays to the strengths of each component: the language model contributes chemical intuition and reasoning about which modifications are likely to help, while deterministic software guarantees that every edit is applied correctly and that the resulting molecule is always structurally valid.

To teach models this editing skill, the researchers assembled a training corpus of 3,332 molecular pairs, each accompanied by reasoning traces that explain why the edits transform an inaccessible molecule into a synthesizable one. The benchmarking results show that SynCraft outperforms state-of-the-art baselines at generating synthesizable analogues with high structural fidelity, meaning the edited molecules remain close to the original designs rather than drifting into unrelated chemical territory. Notably, the framework performed comparably whether it was running on proprietary frontier models or on open-weight backends, an important practical finding because it suggests the approach does not depend on access to the most expensive commercial systems. Laboratories with modest budgets can deploy the same chemistry on locally hosted models.

Perhaps the most striking validation of the approach is retrospective: SynCraft, guided by interaction-aware prompting that describes the protein-ligand contacts a molecule must preserve, successfully replicated the kind of editing judgments that expert medicinal chemists make intuitively. In tests on inhibitors of PLK1, a well-studied cancer target, the system’s proposed edits mirrored expert reasoning about which structural features to protect and which to sacrifice. The framework then went a step further into prospective territory, rescuing high-scoring RIPK1 candidate molecules that had been generated by earlier molecular generation models but discarded because they could not be synthesized. These were, in effect, good ideas trapped behind a synthetic wall, and SynCraft found the edits that let them through without destroying their binding profiles.

To make the workflow practical rather than merely demonstrative, the researchers packaged SynCraft as an agent skill, a modular capability that an autonomous AI agent can invoke. They demonstrated an end-to-end rescue workflow on candidate molecules generated for the SARS-CoV-2 main protease, the target that anchored much of the pandemic-era antiviral effort. The workflow verified that edited molecules retained their binding modes, checking interaction preservation with tools such as the protein-ligand interaction profiler, so that the rescue operation could be audited at the level of individual hydrogen bonds and hydrophobic contacts rather than trusted on faith. This kind of verification matters in a field where black-box outputs have historically been greeted with justified skepticism by experimentalists.

The broader significance of the work lies in how it repositions large language models within chemistry. Much of the early excitement, and disappointment, around LLMs in molecular design came from attempts to have them generate molecules directly, treating chemical structures as just another text format. The results were often syntactically broken or chemically nonsensical, and studies measuring the robustness of chemical language models to different molecular representations revealed how brittle the approach was. SynCraft belongs to a more mature second wave in which the language model serves as a reasoning engine over structured, tool-verifiable operations, a pattern that echoes the chain-of-thought techniques that unlocked reasoning in general-purpose models. The model thinks; deterministic chemistry software acts; validators check the result.

Accessibility may prove as consequential as accuracy. The SynCraft implementation, reproduction scripts for every experiment, and the agentic skill package have been released under an MIT license on GitHub, with the test sets, training corpus, inference outputs and case-study structures deposited openly on Figshare. Any group running generative drug design pipelines can therefore bolt synthesizability rescue onto their existing workflow without licensing barriers. As generative models continue to flood virtual screening campaigns with candidates, the gap between what AI can imagine and what chemists can build has been the field’s most persistent embarrassment. A framework that closes that gap with minimal, principled edits, while preserving the binding interactions that make a molecule worth making, turns discarded designs into a usable reservoir of drug candidates, and suggests that the future of AI-driven discovery lies less in generating more molecules than in knowing exactly which few atoms to change.

Subject of Research: Using large language models to optimize the synthesizability of AI-generated drug candidate molecules through predicted structural edit sequences

Article Title: Guiding large language models to predict edit sequences for molecular synthesizability optimization

Article References: Li, J., & Lai, L. (2026). Guiding large language models to predict edit sequences for molecular synthesizability optimization. Nature Machine Intelligence. https://doi.org/10.1038/s42256-026-01304-x

Image Credits: AI Generated

DOI: 10.1038/s42256-026-01304-x

Keywords: large language models, molecular synthesizability, drug discovery, generative AI, medicinal chemistry, SynCraft, molecular editing, retrosynthesis, SARS-CoV-2 main protease, RIPK1, PLK1, cheminformatics